Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 3
1(25.0%)
Phase 4
1(25.0%)
4Total
Phase 2(2)
Phase 3(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05253417Phase 2Completed

The CANabidiol Use for RElief of Short Term Insomnia

Role: lead

NCT04997954Phase 4Unknown

EMERALD TRIAL Open Label Extension Study

Role: collaborator

NCT03690791Phase 3Unknown

Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease

Role: collaborator

NCT04997395Phase 2Completed

Feasibility of Cannabidiol for the Treatment of Long COVID

Role: lead

All 4 trials loaded